Skip to main content
$40.49 $1.39 (3.6%)

03:42 PM EST on 12/01/20

Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Current Price $40.49 Mkt Cap $5.3B
Open $39.75 P/E Ratio 250.12
Prev. Close $39.10 Div. (Yield) $0.00 (0.0%)
Daily Range $39.26 - $40.60 Volume 794,919
52-Wk Range $12.71 - $41.55 Avg. Daily Vol. 2,347,741


How do you think NASDAQ:HALO will perform against the market?

Add Stock to CAPS Watchlist

All Players

287 Outperform
41 Underperform

All-Star Players

33 Outperform
6 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:HALO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

manirg (< 20)
Submitted October 16, 2014


davidmelnikov (< 20)
Submitted December 19, 2006

1. roche deal not that great.2. stock overvalued3. company exists of 19 employees4. no disaster recovery in place, company can be wiped out.5. to many pumpers/blogs bringing the stock price up for no reason.


Fools bullish on NASDAQ:HALO are also bullish on:

Fools bearish on NASDAQ:HALO are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about HALO.


Member Avatar LohShiSan (91.93) Submitted: 4/26/2020 9:10:48 PM : Outperform Start Price: $23.94 NASDAQ:HALO Score: +40.58

Hi Guys, you might never heard of Halozyme Therapeutics, Inc. The company provides drug-delivery technology and is on the verge of turning profitable for the first time.The stock gained 23% this week and we believe this momentum can continue throughout 2020. Here’s is the reason why.Halozyme’s newfound profits are a result of a recent pivot in its business model. Last November, the company moved away from developing cancer treatments in-house, to focus on its drug-delivery system, Enhanze.The business generates mid-single digit royalties from a handful of products already sold by partners, with more than a dozen others in clinical trials. Management believes this can grow to a $1 billion operation over the next seven years.Halozyme’s new business model is expected to lead to its first ever annual profit of $0.63 a share this year, rising to $1.43 in 2021.
History has shown that buying a company on the verge of sustainable profitability can prove to be a lucrative investment. This could be especially true for Halozyme, which is currently valued at just 15.5x expected forward profits.Insiders agree the stock has more upside potential. Back in March, a member of the Board of Directors bought about $750,000 worth of the company, on the open market. In addition, management has pledged to repurchase about $150 million of shares in 2020.

It’s also worth noting that HALO carries a Smart Score of 10/10 on TipRanks. This proprietary score utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor of future outperformance.On top of the positive aspects mentioned already, the Smart Score indicates that the company has seen improving sentiment from analysts, hedge funds and financial bloggers. Hope my tips help! Good Luck.


Member Avatar denbaldwin1 (< 20) Submitted: 10/5/2017 11:25:41 AM : Underperform Start Price: $17.60 NASDAQ:HALO Score: -85.60

Earnings will be weak


Member Avatar wisnasty60 (< 20) Submitted: 7/8/2016 12:40:08 PM : Outperform Start Price: $9.19 NASDAQ:HALO Score: +266.05

An established biotech company with a successful approved delivery platform with partnerships with other major pharmaceutical drug companies. The company also has a pancreatic drug treatment in phase III trials that has the potential to treat a disease without many viable treatment options.


Find the members with the highest scoring picks in HALO.

Score Leader


unguja64 (45.69) Score: +1,330.14

The Score Leader is the player with the highest score across all their picks in HALO.

Member Name Member
Call Time
Score Commentary
unguja64 45.69 8/25/2006 Outperform 3Y $2.48 +1,523.02% +199.43% +1,323.58 1 Comment
coach1983 < 20 9/18/2006 Outperform 3Y $2.54 +1,485.83% +194.76% +1,291.06 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. foolduke 75.42 11/20/2006 Outperform NS $2.65 +1,420.00% +176.96% +1,243.04 0 Comment
acsimon 39.07 10/16/2006 Outperform NS $2.67 +1,408.61% +184.53% +1,224.08 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. pokerden 48.52 10/11/2006 Outperform 3Y $2.68 +1,402.99% +188.07% +1,214.91 1 Comment
Quality101 < 20 9/21/2006 Outperform 3Y $2.68 +1,402.99% +192.30% +1,210.68 1 Comment
czg3000 45.29 11/24/2006 Outperform 1Y $2.80 +1,338.57% +176.97% +1,161.60 0 Comment
Joe1988 84.18 11/24/2006 Outperform 1Y $2.82 +1,328.37% +177.96% +1,150.41 2 Comments
kh00 60.12 11/30/2006 Outperform 3Y $2.85 +1,313.33% +175.25% +1,138.08 0 Comment
dawg99pound < 20 11/27/2006 Outperform NS $2.88 +1,298.61% +177.05% +1,121.57 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for HALO.